---
title: U87 CART in Treatment of Advanced Solid Tumor
nct_id: NCT05605197
overall_status: UNKNOWN
phase: PHASE1
sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
study_type: INTERVENTIONAL
primary_condition: Pancreatic Cancer
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05605197.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05605197"
ct_last_update_post_date: 2024-05-28
last_seen_at: "2026-05-12T06:07:05.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# U87 CART in Treatment of Advanced Solid Tumor

**Official Title:** Clinical Study to Evaluate the Safety and Efficacy of U87 CART in Treatment of Advanced Solid Tumor

**NCT ID:** [NCT05605197](https://clinicaltrials.gov/study/NCT05605197)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 12
- **Lead Sponsor:** Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- **Collaborators:** Shanghai 10th People's Hospital
- **Conditions:** Pancreatic Cancer, Solid Tumor, Adult
- **Start Date:** 2022-10-19
- **Completion Date:** 2025-10-08
- **CT.gov Last Update:** 2024-05-28

## Brief Summary

This is a single center, open-label, phase 1 study to evaluate the safety and efficacy of U87 CART in treating advanced solid tumor .

## Detailed Description

Following consent, patients must have tumor tissue evaluated by IHC assay. Patients meeting all eligibility criteria will undergo a leukapheresis procedure to collect autologous mononuclear cells for manufacture of investigational drug product (U87). Following manufacture of the drug product, subjects will receive preconditioning prior to U87 infusion. All subjects will be asked to continue to undergo long-term gene safety follow-up.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Voluntary informed consent is given;
2. Age 18 to 75;
3. Patients with pathologically confirmed advanced solid tumor who have failed first-line therapy; or patients who are intolerant to first-line standard therapy and voluntarily give up standard therapy;
4. Immunohistochemical (IHC) staining of tumor tissue samples from patients was positive for U87 specific antigen (≥ 2 +, and the expression rate was ≥ 20%);
5. Expected survival ≥12 weeks;
6. Measurable tumor lesions according to RECIST 1.1;
7. ECOG performance score 0-1;
8. Sufficient venous access for mononuclear cell collection;
9. HBc Ab positive, HBsAg negative can be included in the group when the PCR detection of HBV DNA is negative;
10. Patients should maintain adequate organ function;
11. Dyspnea (CTCAE v5.0) ≤ Grade 1; Blood oxygen saturation\>91% without oxygen inhalation;
12. Pregnancy test was negative in women of childbearing age; Both male and female subjects should agree to use effective contraceptives during the treatment period and within the following year;

Exclusion Criteria:

1. Pregnant or lactating women;
2. Uncontrolled active infections;
3. Active Syphilis, HIV, hepatitis B or hepatitis C infection;
4. Congenital immunodeficiency;
5. Have serious allergic reaction to any drug to be used in this study;
6. Other incurable malignant tumors in the past three years;
7. History or presence of clinically relevant CNS pathology such as epilepsy, Cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any CNS-related autoimmune disease;
8. Have undergone cardiac angioplasty or stent implantation within 12 months, or have a history of myocardial infarction, unstable angina or other clinically significant heart diseases;
9. Subjects requiring anticoagulation or long-term antiplatelet therapy;
10. Subjects who have undergone major surgery or significant trauma within four weeks before enrolled in the study.
11. Other situations that the investigator thinks are not suitable for participating in this study.
```

## Arms

- **U87 CAR-T cells** (EXPERIMENTAL) — The Patients are enrolled into 2 dose level cohorts in sequence

## Interventions

- **U87 CAR-T** (DRUG) — Subjects will be pretreated with cyclophosphamide 250\~500 mg/m2( body surface area) for 3 days prior to Intravenous injection of U87, followed by intraartery of U87 14 days later with intravenous IL-2. Researchers can perform intratumoral injection based on their judgment.This study will explore two dose of dose 1 (DL-1): 1×106 (±20%) to dose 2 (DL-2): 1×107 (±20%),each group was enrolled in 3\~6 patients.

## Primary Outcomes

- **Incidence of Adverse events after U87 CAR-T cells infusion [Safety and Tolerability]** _(time frame: 28 days post administration of CAR-T-cells)_ — Therapy-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0) Dose-limiting toxicity after U87 CAR-T cells infusion.

## Secondary Outcomes

- **Disease control rate (DCR) of U87 CAR-T cells treatment in advanced solid tumor. [Effectiveness]** _(time frame: 2 years post CAR T cell infusion)_
- **Objective response rate (ORR) of U87 CAR-T cells treatment in advanced solid tumor. [Effectiveness]** _(time frame: 2 years post CAR T cell infusion)_
- **Duration of Response (DOR) of U87 CAR-T cells treatment in advanced solid tumot[Effectiveness]** _(time frame: 2 years post CAR T cell infusion)_
- **Progress-free survival(PFS) of U87 CAR-T cells treatment in advanced solid tumor[Effectiveness]** _(time frame: 2 years post CAR T cell infusion)_
- **Overall survival(OS) of U87 CAR-T cells treatment in advanced solid tumor [Effectiveness]** _(time frame: 2 years post CAR T cell infusion)_
- **Pharmacokinetics of U87 CAR-T cells** _(time frame: 2 years post CAR T cell infusion)_
- **Pharmacokinetics of U87 CAR-T cells** _(time frame: 2 years post CAR T cell infusion)_
- **Pharmacokinetics of U87 CAR-T cells** _(time frame: 2 years post CAR T cell infusion)_
- **Pharmacodynamics of U87 CAR-T cells** _(time frame: 2 years post CAR T cell infusion)_

## Locations (1)

- China Shanghai 10th People's Hospital, Shanghai, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.china shanghai 10th people's hospital|shanghai||china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05605197.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05605197*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*